NASDAQ : RDHL
RedHill Biopharma Ltd. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · Israel
Last price 0.4166 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.53M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.36M |
| Enterprise Value | -1.73M |
Dates
| Measure | Value |
|---|
| Earnings Date | Sep 30, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 6.08M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.48% |
| Owned by Institutions (%) | 3.08% |
| Float | 5.02M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.34 |
| Quick Ratio | 0.20 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.46 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -22.37% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -1,120.90% |
| Weighted Average Cost of Capital (WACC) | 28.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$184,462 |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 4.90 |
| 52-Week Price Change | -73.44% |
| 50-Day Moving Average | 0.56 |
| 200-Day Moving Average | 0.81 |
| Relative Strength Index (RSI) | 33.70 |
| Average Volume (20 Days) | 904,585 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 128,328 |
| Short Previous Month | 211,200 |
| Short % of Shares Out | 1.46% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.15 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.99M |
| Pretax Income | -10.87M |
| Net Income | -2.40M |
| EBITDA | -7.90M |
| EBIT | -7.99M |
| Earnings Per Share (EPS) | n/a |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.16M |
| Total Debt | 1.08M |
| Net Cash | 4.08M |
| Net Cash Per Share | $0.67 |
| Equity (Book Value) | -1.08M |
| Book Value Per Share | n/a |
| Working Capital | -16.99M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.76M |
| Capital Expenditures | -15,000 |
| Depreciation & Amortization | 89,000 |
| Net Borrowing | -339,000 |
| Free Cash Flow | -7.78M |
| FCF Per Share | -$1.28 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -101.69% |
| FCF Yield | -329.87% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 1,131.53% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -24.01 |
| Piotroski F-Score | n/a |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |